Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

Main Article Content

April W. Armstrong
Robert Bissonnette
Phililp M. Brown
Anna Tallman
a:1:{s:5:"en_US";s:9:"Dermavant";}

Kim A. Papp

Keywords

Tapinarof, Aryl Hydrocarbon Receptor Agonist, Treat to Target, Efficacy, Treatment Targets, Plaque Psoriasis, Topical

References

1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76:290–298.

2. Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009;23:5–70.

3. Mahil SK, et al. Br J Dermatol. 2020;182:1158–1166.

4. Strober BE, et al. Dermatol Ther. 2019;9:5–18.

5. Bagel J and Stein Gold L. J Drugs Dermatol. 2017;16:1209–1222.

6. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–2207.

7. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432-470.

8. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed 22 July 2022.

9. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229.

10. Lebwohl M, et al. Presentation at: European Academy of Dermatology and Venereology; October 28 - November 1, 2020.

11. Strober B, et al. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.06.1171.

12. National Psoriasis Foundation. Treat to Target. https://www.psoriasis.org/treat-to-target/. Accessed August 2022.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.124

Article Details

How to Cite
Armstrong, A. W. ., Bissonnette, R. ., Brown, P. M. ., Tallman, A., & Papp, K. A. . (2023). Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 7(2), s124. https://doi.org/10.25251/skin.7.supp.124
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>